Frontiers in Pharmacology

Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study

By Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang, Hsuan-Yuan Chang, Yu-Min Lin

Cohort study of 189,156 peoplePopulations

The paper

Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang, Hsuan-Yuan Chang, Yu-Min Lin

Chi Mei Medical Center

Frontiers in Pharmacology, 31 Jul 2026

doi.org/10.3389/fphar.2026.1877392 PubMed 42601938

Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression